Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group

被引:3
|
作者
Gwyther, SJ
Nielsen, OS
Judson, IR
van Glabbeke, M
Verweij, J
机构
[1] E Surrey Hosp, Surrey & Sussex NHS Trust, Surrey RH1 5RH, England
[2] Aarhus Univ Hosp, DK-800 Aarhus C, Denmark
[3] Inst Canc Res, CRC, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England
[4] EORTC Data Ctr, B-1200 Brussels, Belgium
[5] Rotterdam Canc Inst, Daniel den Hoed Klin, NL-3008 AE Rotterdam, Netherlands
[6] Univ Hosp, NL-3008 AE Rotterdam, Netherlands
关键词
claimed responses; independent radiological; review; peer review; response rate;
D O I
10.1097/00001813-200007000-00003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Soft Tissue and Bone Sarcoma Group (STBSG) of the EORTC ran a phase II study to assess the therapeutic activity of high-dose ifosfamide in patients with advanced soft tissue sarcomas by means of response rate (RR). Investigators claiming a response submitted the relevant chest radiographs (CXR) or scans to two other members of the STBSG for peer review. The reviewers completed a questionnaire indicating overall response or reasons for rejecting the claimed responses. An independent radiologist also reviewed the cases and he was blinded to the results of the peer review until the study was concluded. Twenty-two patients were reviewed by the radiologist and peer review, and the completed questionnaires were retrospectively reviewed. Two differences were noted, one partial responder (PR) was regarded as stable disease by the radiologist and one PR by peer review was determined a complete response by the radiologist. The radiologist found subsequent evidence of progressive disease in three patients who initially showed a PR, whilst the review group noted only one. This study suggests peer review in this tumor type is a satisfactory method of achieving an accurate, objective RR. [(C) 2000 Lippincott Williams & Wilkins].
引用
收藏
页码:433 / 437
页数:5
相关论文
共 50 条
  • [21] Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
    Le Cesne, A
    Blay, JY
    Judson, I
    Van Oosterom, A
    Verweij, J
    Radford, J
    Lorigan, P
    Rodenhuis, S
    Ray-Coquard, I
    Bonvalot, S
    Collin, F
    Jimeno, J
    Di Paola, E
    Van Glabbeke, M
    Nielsen, OS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) : 576 - 584
  • [23] MITOMYCIN-C (MCC) IN ADVANCED SOFT-TISSUE SARCOMA - A PHASE-II STUDY OF THE EORTC SOFT-TISSUE AND BONE SARCOMA GROUP
    VANOOSTEROM, AT
    SANTORO, A
    BRAMWELL, V
    DAVY, M
    MOURIDSEN, HT
    THOMAS, D
    SYLVESTER, R
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (04): : 459 - 461
  • [24] GRADING OF SOFT-TISSUE SARCOMAS - EXPERIENCE OF THE EORTC SOFT-TISSUE AND BONE SARCOMA GROUP
    VANUNNIK, JAM
    COINDRE, JM
    CONTESSO, C
    ALBUSLUTTER, CE
    SCHIODT, T
    SYLVESTER, R
    THOMAS, D
    BRAMWELL, V
    MOURIDSEN, HT
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (15) : 2089 - 2093
  • [25] Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group phase II study
    Saeter, G
    Alvegard, TA
    Monge, OR
    Strander, H
    Turesson, I
    Klepp, R
    Soderberg, M
    Wist, E
    Raabe, N
    Erlanson, M
    Solheim, OP
    Hannisdal, E
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (10) : 1551 - 1558
  • [26] Phase II trial of first-line high-dose ifosfamide in advanced adult soft tissue sarcoma
    Trarbach, T
    Scheulen, ME
    Schroder, J
    Stuschke, M
    Seeber, S
    Schutte, J
    TUMORDIAGNOSTIK & THERAPIE, 1997, 18 (02) : 57 - 60
  • [27] Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas
    Palumbo, R
    Palmeri, S
    Antimi, M
    Gatti, C
    Raffo, P
    Villani, G
    Toma, S
    ANNALS OF ONCOLOGY, 1997, 8 (11) : 1159 - 1162
  • [28] Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis
    Kollar, A.
    Jones, R. L.
    Stacchiotti, S.
    Gelderblom, H.
    Guida, M.
    Boccone, P.
    Steeghs, N.
    Safwat, A.
    Katz, D.
    Duffaud, F.
    Sleijfer, S.
    van sder Graaf, W.
    Touati, N.
    Litiere, S.
    Marreaud, S.
    Gronchi, A.
    Kasper, B.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study.
    Gelderblom, H.
    Blay, J.
    Seddon, B. M.
    Leahy, M.
    Ray-Coquard, I. L.
    De Brauwer, A.
    Veyt, E.
    Weitman, S. D.
    Hogendoorn, P. C.
    Hohenberger, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma:: a study by the EORTC Soft Tissue and Bone Sarcoma Group
    Judson, I
    Radford, JA
    Harris, M
    Blay, JY
    van Hoesel, Q
    le Cesne, A
    van Oosterom, AT
    Clemons, MJ
    Kamby, C
    Hermans, C
    Whittaker, J
    di Paola, ED
    Verweij, J
    Nielsen, S
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (07) : 870 - 877